Clinical Trial Update: A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating an A4I antagonist for relapsing multiple sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• A4I Antagonist

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Multiple Sclerosis | Phase 2 | Status: WITHDRAWN